2003
Successful Treatment of Human Granulocytic Ehrlichiosis in Children Using Rifampin
Krause PJ, Corrow CL, Bakken JS. Successful Treatment of Human Granulocytic Ehrlichiosis in Children Using Rifampin. Pediatrics 2003, 112: e252-e253. PMID: 12949322, DOI: 10.1542/peds.112.3.e252.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisYears of ageSuccessful treatmentGranulocytic ehrlichiosisTick-borne infectious diseaseFlu-like illnessTreatment of choiceHospital admissionClinical featuresSerious infectionsInfectious diseasesPhagocytophilum infectionRifampinAnaplasma phagocytophilumPermanent stainingChildrenInfectionTreatmentEhrlichiosisAgeYearsAdmissionIllnessDiseaseDoxycyclineIncreasing health burden of human babesiosis in endemic sites.
KRAUSE PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, TELFORD SR, Sikand V, Ryan R, Persing D, RADOLF JD, Spielman A, _ _. Increasing health burden of human babesiosis in endemic sites. American Journal Of Tropical Medicine And Hygiene 2003, 68: 431-6. PMID: 12875292, DOI: 10.4269/ajtmh.2003.68.431.Peer-Reviewed Original ResearchConceptsYears of ageEndemic sitesCommunity-based serosurveysClinical spectrumHealth burdenPeople 20Borrelial infectionHuman infectionsBabesial infectionMore older adultsBabesia microtiBabesial antigensOlder adultsHuman babesiosisYoung adultsInfectionBorrelia burgdorferiIncidenceThree-fourthsAdultsAgePrudence IslandSeroprevalenceSerosurveyHospital
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter Surface ProteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data